Replies to post #220796 on Biotech Values

[DewDiligence]

Shareholders approve VTL reverse-merger into IMUX (Immunic):

https://www.globenewswire.com/news-release/2019/04/04/1797376/0/en/Vital-Therapies-Inc-Announces-Stockholder-Approval-of-Business-Combination-with-Immunic-AG.html

“…this outcome represents the best option for our stockholders, as the transaction is expected to create a publicly listed company with a strong cash position and promising portfolio of multiple oral drug candidates with best-in-class potential for the treatment of highly-prevalent and debilitating autoimmune and inflammatory diseases. I look forward to handing the baton to Immunic’s Chief Executive Officer, Daniel Vitt, Ph.D., and his experienced team of executives to enable the further development of these important drug candidates.”

…the Boards of Directors of both Vital Therapies and Immunic unanimously approved the business combination, which is expected to be consummated by mid-April 2019. In connection with the closing of the transaction, Vital Therapies will change its name to Immunic, Inc. and the Company’s shares will commence trading on The Nasdaq Stock Market under the symbol “IMUX”.